Dr Platzbecker on the COMMANDS Trial in Lower-Risk MDS With

Uwe Platzbecker, MD, discusses key findings from the phase 3 COMMANDS trial with luspatercept in patients with lower-risk myelodysplastic syndrome with anemia, as well as the clinical implications of FDA approval of luspatercept for patients in this population.

Related Keywords

United States , Uwe Platzbecker , European Union , University Hospital Leipzig , D , Commands Trial , Nct03682536 , Luspatercept , Patients With Lower Risk Myelodysplastic Syndrome Anemia ,